🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Recruitingn/aAges 18 Years - anyAllUniversity of California, Los Angeles
NCT05419726 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study) * \>18 years of age and willing to participate * Male or post-menopausal females Exclusion Criteria: * History of prior neck surgery and /or neck irradiation * Use of beta blocker agents * Use of any other glucose lowering medication * History of neuropathic disorders (e.g. diabetic neuropathy) * Diabetic patients * Individuals without normal thyroid function * Individuals with cancer * Any significant chronic disease or renal, hepatic or endocrine disease * Current smokers * Inability of patient to provide consent either for medical reasons or psychiatric reasons
💊

What it tests

  • Semaglutide Injectable Product (not provided by the study)
📍

Where

1 site
UCLA Health
Los Angeles, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy